Luteinizing hormone secretion elicited in a ligand-independent activation of progesterone receptor manner at pituitary level in the rat: differential effect of two selective estrogen receptor modulators

Neurosci Lett. 2000 Aug 4;289(2):111-4. doi: 10.1016/s0304-3940(00)01270-2.

Abstract

In the absence of progesterone, RU486 reduced basal and luteinizing hormone-releasing hormone (LHRH)-stimulated LH secretion in pituitaries from proestrous rats, a fact which evidences a ligand-independent activation of progesterone receptors (LIAPR) at pituitary level. This was also observed in pituitaries from rats treated with tamoxifen, and absent in glands from either ovariectomized or raloxifene-treated animals. Both ovariectomy or raloxifene treatment reduced the stimulatory effect of LHRH on LH secretion, while tamoxifen induced an even higher response. Prolactin (PRL) secretion was unaffected by either RU486 or LHRH, nor it was influenced by ovariectomy or raloxifene treatment. However, treatment with tamoxifen elevated PRL in all groups. These findings indicate that LIAPR is an estrogen-dependent phenomenon at the anterior pituitary of the female rat, and that tamoxifen and raloxifene present agonist and antagonist estrogen activity, respectively, at this level.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Estrogen Receptor Modulators / pharmacology*
  • Female
  • Gonadotropin-Releasing Hormone / pharmacology
  • Luteinizing Hormone / metabolism*
  • Mifepristone / pharmacology
  • Pituitary Gland, Anterior / drug effects
  • Pituitary Gland, Anterior / metabolism*
  • Pregnancy
  • Prolactin / metabolism
  • Raloxifene Hydrochloride / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Progesterone / metabolism*
  • Tamoxifen / pharmacology

Substances

  • Estrogen Receptor Modulators
  • Receptors, Progesterone
  • Tamoxifen
  • Mifepristone
  • Gonadotropin-Releasing Hormone
  • Raloxifene Hydrochloride
  • Prolactin
  • Luteinizing Hormone